Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and89Zr-trastuzumab PET Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Fluorodeoxyglucose F18
  • Positron-Emission Tomography
  • Quinazolines
  • Receptor, ErbB-2
  • Stomach Neoplasms

abstract

  • Afatinib demonstrated antitumor activity in HER2-positive gastric cancer in vivo. (89)Zr-trastuzumab PET specifically delineated HER2-positive gastric cancer and can be used to measure the pharmacodynamic effects of afatinib.

publication date

  • June 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4967936

Digital Object Identifier (DOI)

  • 10.2967/jnumed.112.110239

PubMed ID

  • 23578997

Additional Document Info

start page

  • 936

end page

  • 43

volume

  • 54

number

  • 6